Literature DB >> 32889702

Treatment of renal AA-Amyloidosis associated with human immunodeficiency virus infection: a case report.

Janice Borg1, Jesmar Buttigieg2, Stephen Holwill3, Charles Mallia Azzopardi4.   

Abstract

We present a case of a young adult male who was treated successfully for renal AA-amyloidosis secondary to human immunodeficiency virus (HIV) infection using highly active anti-retroviral therapy (HAART). He presented with lobar pneumonia, acute kidney injury, nephrotic syndrome and newly diagnosed HIV infection and was initiated on HARRT and haemodialysis. Kidney biopsy was consistent with amyloid deposition of the AA-type. His clinical condition improved gradually and after 10 months of therapy, he regained sufficient excretory function to become dialysis independent. Two years later, he remained well, with a recovered CD4 count and a glomerular filtration rate of 63 mL/min/1.73 m2. Patients with renal AA-amyloidosis typically present with slowly progressive chronic kidney disease, often leading to end-stage kidney disease within months. To our knowledge, this is the first reported case of biopsy proven renal AA-amyloidosis in a newly diagnosed HIV positive patient to present with acute kidney injury leading to dialysis dependence over a period of 2 weeks, which was successfully treated using HAART.

Entities:  

Keywords:  Chronic kidney disease; Haemodialysis; Nephrotic syndrome; Renal biopsy

Year:  2020        PMID: 32889702      PMCID: PMC7829295          DOI: 10.1007/s13730-020-00525-2

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  21 in total

1.  Renal amyloidosis in familial Mediterranean fever.

Authors:  Seza Ozen
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

2.  Amyloidosis in association with human immunodeficiency virus infection.

Authors:  P J Cozzi; G M Abu-Jawdeh; R M Green; D Green
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

3.  Secondary systemic amyloidosis: response and survival in 64 patients.

Authors:  M A Gertz; R A Kyle
Journal:  Medicine (Baltimore)       Date:  1991-07       Impact factor: 1.889

4.  Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy.

Authors:  S Mpofu; L S Teh; P J Smith; R J Moots; P N Hawkins
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

5.  The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy.

Authors:  Christina M Wyatt; Susan Morgello; Rebecca Katz-Malamed; Catherine Wei; Mary E Klotman; Paul E Klotman; Vivette D D'Agati
Journal:  Kidney Int       Date:  2008-12-03       Impact factor: 10.612

Review 6.  Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm.

Authors:  Emily S Ford; Camille E Puronen; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

7.  AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.

Authors:  Serge de Vallière; Charles Mary; Jeanna E Joneberg; Samuel Rotman; Roberto Bullani; Gilbert Greub; Julian D Gillmore; Pierre A Buffet; Philip E Tarr
Journal:  Am J Trop Med Hyg       Date:  2009-08       Impact factor: 2.345

8.  Glomerular lesions in HIV-positive patients: a 20-year biopsy experience from Northern Italy.

Authors:  M Nebuloni; G Barbiano di Belgiojoso; A Genderini; A Tosoni; N L; M Heidempergher; P Zerbi; L Vago
Journal:  Clin Nephrol       Date:  2009-07       Impact factor: 0.975

9.  Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient.

Authors:  Kirk M Chan-Tack; Navneet Ahuja; Edward J Weinman; Ravinder K Wali; Anayochukwu Uche; Lisa A Greisman; Cinthia Drachenberg; Philip N Hawkins; Robert R Redfield
Journal:  Am J Med Sci       Date:  2006-12       Impact factor: 2.378

10.  Pattern of renal amyloidosis in South Africa.

Authors:  Muhammed Hassen; William Bates; Mohammed Rafique Moosa
Journal:  BMC Nephrol       Date:  2019-11-09       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.